ScienceMore in Science→
Experimental pancreatic cancer pill shows major survival gain
Researchers reported that daraxonrasib extended survival in metastatic pancreatic cancer patients whose disease had stopped responding to chemotherapy.
Key Takeaways
- Daraxonrasib was tested in 500 patients with metastatic pancreatic cancer.
- Researchers reported average survival of 13.2 months versus 6.7 months on chemotherapy.
DE
DT Editorial Team··via newscientist.com
